Perianal fistulas in Crohn's disease - Biologicals and surgery: Is it worthwhile?;Perianales fistelleiden bei morbus Crohn - Biologika und chirurgie: Ein iohnendes konzept?

Zeitschrift fur Gastroenterologie

Volumn 46, Issue 12, 2008, Pages 1376-1383

  Bode, M ^a   Eder, S ^a   Schürmann, Guido ^a  

^a Allgemein Gefäß und Viszeralchirurgie

Author keywords

Anal fistula; Anti TNF antibodies; Crohn's disease; Infliximab; Surgical therapy

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CIPROFLOXACIN; ETANERCEPT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METRONIDAZOLE; ONERCEPT; PLACEBO; SEMAPIMOD; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANUS FISTULA; CROHN DISEASE; DATA ANALYSIS; DIAGNOSTIC ACCURACY; ENDOSCOPIC ECHOGRAPHY; HUMAN; MEDICAL LITERATURE; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CROHN DISEASE; HUMANS; RECTAL FISTULA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 58149460571     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1027626     Document Type: Review

References (34)

1. Autschbach F. Pathologie der CED. In: Hoffmann J, Kroesen A, Klump B (Hrsg). Chronisch entzündliche Darmerkrankungen. Thieme Verlag, 2004: Kapitel 3.8.3, Seite 113.
2. Gasche C, Scholmerich J, Brynskov J et al. A simple classification of Crohn's disease: report of the Working Party for the World Congress of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000; 6 (1): 8-15
3. Reinshagen M. Klinik des Morbus Crohn In: Hoffmann J, Kroesen A, Klump B (Hrsg). Chronisch entzündliche Darmerkrankungen. Thieme Verlag, 2004: Kapitel 3.1.5, Seite 63.
4. Kroesen AJ. Anorektale Fisteln bei Morbus Crohn In: Hoffmann J, Kroesen A, Klump B (Hrsg). Chronisch entzündliche Darmerkrankungen. Thieme Verlag, 2004: Kapitel 6.3 Seite 245.
5. Baumgart DC, Wiedenmann B, Dignass AU. Biologische Therapie chronisch-entzündlicher Darmerkrankungen. Z Gastroenterol 2003; 41: 1017-1032
6. Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340 (18): 1398-1405
7. Luna-Chadid M, Pérez Calle JL, Mendoza JL et al. Predictors of response to infliximab in patients with fistulizing Crohn's disease. Rev Esp Enferm Dig 2004; 96 (6): 379-381; 382-384
8. van der Hagen SJ, Baeten CG, Soeters PB et al. Anti-TNF-alpha (infliximab) used as induction treatment in case of active proctitis in a multistep strategy followed by definitive surgery of complex anal fistulas in Crohn's disease: a preliminary report. Dis Colon Rectum 2005; 48 (4): 758-767
9. Talbot C, Sagar PM, Johnston MJ et al. Infliximab in the surgical management of complex fistulating anal Crohn's disease. Colorectal Dis 2005; 7 (2): 164-168
10. Poritz LS, Rowe WA, Koltun WA. Remicade does not abolish the need for surgery in fistulizing Crohn's disease. Dis Colon Rectum 2002; 45 (6): 771-775
11. Sabate JM, Villarejo J, Lemann M et al. An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease. Aliment Pharmacol Ther 2002; 16 (6): 1117-1124
12. Ehrenpreis ED, Kane SV, Cohen LB et al. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 1999; 117 (6): 1271-1277
13. Vasiliauskas EA, Kam LY, Abreu-Martin MT et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 1999; 117 (6): 1278-1287
14. Parks AG, Gordon PH, Hardcastle JD. A classification of fistula-in-ano. Br J Surg 1976; 63 (1): 1-12
15. Wolff BG, Culp CE, Beart Jr. RW et al. Anorectal Crohn's disease. A long term perspective. Dis Colon Rectum 1985; 28 (10): 709-711
16. Ahlbäck S, Holmström B, Syk B. Anal fistulography. Acta Radiol 1974; 15: 281-287
17. Bressler B, Sands BE. Review article: Medical therapy for fistulizing Crohn's disease. Aliment Pharmacol Ther 2006; 24 (9): 1283-1293
18. Lichtenstein GR. Treatment of Fistulizing Crohn's Disease. Gastroenterology 2000; 119: 1132-1147
19. Kucharzik T, Maaser C, Lügering A et al. Recent understanding of the IBD pathogenesis: implications for future therapies. Inflamm Bowel Dis 2006; 12 (11): 1068-1083
20. Rijcken E, Krieglstein CF, Anthoni C et al. ICAM-1 and VCAM-1 antisense oligonucleotides attenuate in vivo leucocyte adherence and inflammation in rat inflammatory bowel disease. Gut 2002; 51 (4): 529-535
21. VanDeventer SJH, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Gastroenterology 1997; 113: 383-389
22. Fedorak RN, Gangl A, Elson CO et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 2000; 119 (6): 1473-1482
23. Gasche C, Baskos S, Dejaco C et al. IL-10 secretion and sensitivity in normal human intestine and inflammatory bowel disease. J Clin Immunol 2000; 20 (5): 362-370
24. Schreiber S, Fedorak RN, Nielsen OH et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology 2000; 119 (6): 1461-1472
25. Sands BE, Bank S, Sninsky CA et al. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology 1999; 117: 58-64
26. Sands BE, Winston BD, Salzberg B et al. RHIL-11 Crohn's study group. Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. Aliment Pharmacol Ther 2002; 16: 399-406
27. Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintainance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-885
28. Schürmann GM, Bishop AE, Facer P et al. Increased expression of cell adhesion molecule P-selectin in active inflammatory bowel disease. Gut 1995; 36 (3): 411-418
29. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359 (9317): 1541-1549
30. Schwartz DA, Wiersema MJ, Dudiak KM et al. A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn's perianal fistulas. Gastroenterology 2001; 121 (5): 1064-1072
31. Rutgeerts P. Review article: recurrence of Crohn's disease after surgery - the need for treatment of new leasions. Aliment Pharmacol Ther 2006; Suppl 3: 29-33
32. Schreiber S. Morbus Crohn - Infliximab, Adalimumab und Certolizumab-Pegol: Was bringen die neuen Gegenspieler des TNF-α? Dtsch Med Wochenschr 2007; 132: 1770-1774
33. Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132 (1): 52-65, Epub 2006 Nov 29
34. Rutgeerts P, Van Assche G, Vermeire S. Review article: Infliximab therapy for inflammatory bowel disease - seven years on. Aliment Pharmacol Ther 2006; 23 (4): 451-463